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Abstract
Background: Social mobilisation during new vaccine introductions encourages acceptance, uptake and adherence
to multi-dose schedules. Effective communication is considered especially important for human papillomavirus
(HPV) vaccine, which targets girls of an often-novel age group. This study synthesised experiences and lessons
learnt around social mobilisation, consent, and acceptability during 55 HPV vaccine demonstration projects and 8
national programmes in 37 low and middle-income countries (LMICs) between January 2007 and January 2015.
Methods: A qualitative study design included: (i) a systematic review, in which 1,301 abstracts from five databases
were screened and 41 publications included; (ii) soliciting 124 unpublished documents from governments and
partner institutions; and (iii) conducting 27 key informant interviews. Data were extracted and analysed thematically.
Additionally, first-dose coverage rates were categorised as above 90 %, 90–70 %, and below 70 %, and cross-
tabulated with mobilisation timing, message content, materials and methods of delivery, and consent procedures.
Results: All but one delivery experience achieved over 70 % first-dose coverage; 60 % achieved over 90 %. Key
informants emphasized the benefits of starting social mobilisation early and actively addressing rumours as they
emerged. Interactive communication with parents appeared to achieve higher first-dose coverage than non-
interactive messaging. Written parental consent (i.e., opt-in), though frequently used, resulted in lower reported
coverage than implied consent (i.e., opt-out). Protection against cervical cancer was the primary reason for vaccine
acceptability, whereas fear of adverse effects, exposure to rumours, lack of project/programme awareness, and
schoolgirl absenteeism were major reasons for non-vaccination.
Conclusions: Despite some challenges in obtaining parental consent and addressing rumours, experiences
indicated effective social mobilisation and high HPV vaccine acceptability in LMICs. Social mobilisation, consent, and
acceptability lessons were consistent across world regions and HPV vaccination projects/programmes. These can be
used to guide HPV vaccination communication strategies without additional formative research.
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Background
Low and middle-income countries (LMICs) carry the
highest burden of cervical cancer, accounting for 85 % of
global incidence and 90 % of related mortality [1, 2].
Gardasil® and Cervarix® became available in 2006–2007
as vaccines against human papillomavirus (HPV), the
main causative agent of cervical cancer [3, 4]. HPV
vaccination has become a key component of compre-
hensive cervical cancer prevention and by August
2015 was being delivered in over 80 countries and
territories worldwide in ‘demonstration projects’ or
national programmes [1, 4–6].
To introduce a new vaccine successfully, early and
active engagement of policy-makers, practitioners, and
communities is necessary. Social mobilisation is pro-
moted by the United Nations Children’s Fund (UNICEF)
and the World Health Organization (WHO) as a com-
munication process that engages and motivates a wide
range of partners at all levels to raise awareness of, and
demand for, a particular objective [7, 8]. Some specific
considerations are required for HPV vaccination [7].
First, while routine vaccination is generally provided to
children aged less than 1 year, HPV vaccine is typically
delivered to adolescent girls aged between 9 and 13 years,
or older if catch-up campaigns are conducted [4].
Providing vaccination to this age group raises issues
around informed consent, including how parental con-
sent should be sought prior to vaccination [9–11].
Second, HPV vaccination is primarily delivered to girls
rather than both sexes. Third, delivering vaccination at
school, a common strategy for HPV vaccination, is novel
in some countries [6, 12, 13].
Social mobilisation is intended to increase HPV
vaccination acceptability among girls, parents, and
respected influencers. Acceptability, the tacit recognition
that HPV vaccination is worthwhile, is crucial for high
vaccination coverage and effectiveness [14, 15]. Research
indicates that mobilisation activities that focus on creat-
ing awareness, providing accurate information, building
acceptability and sustaining demand for HPV vaccin-
ation [9, 10, 16, 17], are most effective in countering the
rumours and misinformation that have negatively influ-
enced some HPV vaccination programmes [18, 19].
As part of broader research on lessons learnt from
HPV vaccination demonstration projects and national
programmes in LMICs [20], this study synthesised social
mobilisation and consent experiences and their associa-
tions with acceptability.
Methods
A qualitative study design was chosen, including a sys-
tematic review of published and unpublished literature
and in-depth key informant interviews [20]. A mapping
exercise identified 37 LMICs with at least 1 year of
experience implementing HPV vaccine demonstration
projects or national programmes as of January 2015.
Authors searched five databases systematically for pub-
lished literature (i.e., Medline, Embase, Global Health,
Africa-wide Info, ADOLEC), using a combination of
keyword and free-text terms related to HPV vaccination
and country names. In total, 1301 abstracts were identi-
fied for screening. Authors purposively searched two
databases (i.e., ProQuest, Open Grey), the WHO web-
site, and Ministry of Health (MoH) websites of the
selected countries for unpublished literature. Authors
additionally requested unpublished reports of country
experience from country key informants.
Interviews, using a standardized guide, were con-
ducted with in-country representatives to fill country-
specific data gaps. After comprehensive review of the
literature; 33 countries were approached, 10 country
representatives were unresponsive or refused inter-
views. In total 27 interviews were conducted with
representatives from 23 countries. All of the 27 inter-
viewees had a coordinating role in the projects or
programmes about which they were interviewed; 16
were Ministry of Health representatives (EPI team
members or equivalent), nine were representatives
from partner NGOs, and two were doctors/researchers.
Interviews were conducted by telephone or in-person, re-
corded, and transcribed in English as necessary. A topic
guide was adapted from WHO’s new vaccine introduction
guidelines, it included questions on social mobilisation
timing, frequency, messages, materials, target audience;
consent processes and reasons for vaccine acceptability or
refusal [21].
Data from literature and interview sources were ex-
tracted onto an Excel spread sheet using thematic head-
ings and sub-headings developed from WHO’s new
vaccine introduction guidelines (e.g., social mobilisation
timing, frequency, messages, materials, target audience;
type of consent; vaccine acceptability rates and reasons)
[21]. Data were analysed thematically using three a priori
themes (i.e., social mobilisation, consent, acceptability),
while allowing for emerging themes. First-dose HPV
vaccination coverage, obtained from survey or admin-
istrative reports, was categorised as ‘high’ for above
90 % coverage, ‘medium’ for 70–90 %, and ‘low’ for
below 70 % and cross-tabulated with social mobilisa-
tion strategies and consent procedures to infer the
‘success’ of the different methods. Reasons for vaccin-
ation acceptance and refusal, reported in post-delivery
surveys, were ranked highest to lowest by frequency.
The three most common reasons in each survey were
extracted, scored as ‘3’ for most common, ‘2’ for
second-most common, and ‘1’ for third - most com-
mon, and scores added to indicate the most common
reasons cited across surveys.
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Results
Extent and nature of sources
In total, 41 published articles, 9 conference abstracts,
124 unpublished documents and 27 key informant in-
terviews (KIIs) were included in analysis, covering 72
HPV vaccine delivery experiences in 37 LMICs. A de-
livery experience was defined as HPV vaccine delivery
to a specific target population (e.g., age range in years,
school grade), using a specific vaccination venue (e.g.,
health facility-based, school-based, outreach, or a com-
bination) within a specific project/programme, as de-
fined by funding source. Not all vaccine delivery
experiences collected information covering all data ex-
traction themes.
Social mobilisation
Data on social mobilisation activities were available for
47/72 (65 %) of HPV delivery experiences in 30 of 37
countries. Overall, almost half (33/72; 46 %) of delivery
experiences reported both social mobilisation and first-
dose HPV vaccination coverage, of which 19/33 (58 %)
reported over 90 % coverage rates (Table 1). Sub-themes
related to social mobilisation were target audiences,
messages, communication channels, timing and dur-
ation, and rumour management.
Target audiences
In total, 38/47 (81 %) experiences reporting social mobil-
isation mentioned target audiences. Primary target audi-
ences were usually parents or girls. Secondary target
audiences included communities and credible influencers.
Credible community influencers were identified in nine
experiences as the most common information sources for
parents and included health-workers, teachers/school di-
rectors, community or religious leaders and influential
family members [6, 22]. Credible national influencers in-
cluded members of royalty, wives of elected officials, na-
tional and sub-national political leaders, and entertainers
(e.g., television stars), who were encouraged to launch
campaigns and champion HPV vaccination to increase
confidence and interest among both primary and second-
ary target audiences [23–25]. When the MoH was in-
volved, social mobilisation typically started at national
level, gaining support of national influencers [26].
Messages
Approximately half (24/47; 51 %) of experiences report-
ing social mobilisation also reported message content
(Table 1). The vast majority of messages were framed
around the ‘anti-cancer’ benefits of vaccination rather
than prevention of a sexually transmitted infection
(STI). Messaging was categorised as (i) logistical only,
e.g., vaccination venues, dates, eligibility; (ii) informa-
tional, e.g., logistical information plus basic descriptions
of vaccine safety and cervical cancer risk; or (iii) com-
prehensive, e.g., providing further detailed information
on cervical cancer epidemiology and/or the extent of
vaccine action against HPV. Informational messages,
which combined vaccination logistics and simple expla-
nations of cervical cancer and vaccine safety, were asso-
ciated with highest coverage compared with either
simply logistical or fully comprehensive messages
(Table 1). For example, the information required was de-
scribed by one KII:
“Parents thought the vaccine was new, has not been
widely used and may have some health consequences.
They had also other questions that required explaining,
e.g., why children of a certain age and only girls are
being vaccinated. Could the vaccine affect their
fertility?” (KII, Country 26)
Communication approaches
In total, 33/47 (70 %) experiences reporting social mobil-
isation also reported on communication approaches used
(Table 1). Various approaches and materials were used to
reach target audiences. Communication approaches were
Table 1 Social mobilisation and consent procedures by first-dose
HPV vaccination coverage
Social mobilisation and consent 1st dose coverage reported,
n (%)a
>90 % 70–90 % <70 %
Total number (%) reporting both social
mobilisation and first-dose coverage (n = 33)b
19 (58) 11 (33) 3 (9)
Start of mobilisation prior to vaccination (n = 16)c
Within 1–2 weeks of vaccination 2 (50) 2 (50) 0
3 weeks - less than 2 months 3 (60) 2 (40) 0
2–3 months 3 (43) 3 (43) 1 (14)
Message content (n = 24)d
Logistics only 4 (67) 2 (33) 0
Informational (logistics and cervical cancer) 9 (82) 1 (9) 1 (9)
Comprehensive (detailed) 4 (57) 2 (29) 1 (14)
Materials and approaches (n = 32)e
Interactive 1 (50) 1 (50) 0
Non-interactive 1 (17) 4 (67) 1 (17)
Both interactive and non-interactive 16 (67) 6 (25) 2 (8)
Consent procedures (n = 32)f
Written consent by parents/guardians (opt-in) 9 (50) 6 (33) 3 (17)
Implied (opt-out) consent by parents/
guardians (opt-out)
8 (73) 3 (27) 0
Changed from written to implied consent 3 (100) 0 0
NB: aNumber (%) of delivery experiences that reported first dose HPV coverage;
b33/72 experiences reported both first-dose coverage and social mobilisation;
c16/33 of these experiences also reported when mobilisation started prior to
vaccination; d32/33 of these experiences also reported message delivery
methods; e32/33 of these experiences also reported materials; f32/33 of
these experiences also reported consent procedures
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categorised as interactive (e.g., one-to-one or group meet-
ings at schools or health facilities, home visits by health-
workers) or non-interactive (e.g., leaflets, posters, loud-
speaker, radio, or television announcements). Over half of
experiences using interactive approaches (17/26) achieved
high first-dose coverage (over 90 %) compared to (1/6)
17 % for those using only non-interactive approaches
(Table 1). For example, parents in one experience who re-
ported they had attended a teacher-parent meeting about
vaccination were more likely to have a vaccinated daugh-
ter compared to parents who did not report attending
meetings [22]. While interactive approaches were report-
edly more successful than non-interactive in influencing
HPV vaccination uptake, most experiences (24/33; 73 %)
used a combination of communication approaches [26].
For example:
“We held two meetings at school, but parental
involvement was a bit difficult; not many came
because they were busy with their jobs. And then
through TV or radio, they were informed” (KII,
Country 5)
“Vaccination days were announced by radio but
everyone has a mobile phone and we could have made
better use of texting.” (KII, Country 25)
Timing and duration of activities
In total, 16/47 (34 %) experiences reporting social mobil-
isation also reported on timing of mobilisation activities.
Seven experiences started 2 to 3 months prior to com-
mencing vaccination, while nine others started less than
2 months before vaccination. Timing did not appear to
be correlated with vaccine coverage achieved (Table 1);
however, KIIs reported they had encountered problems
during delivery when mobilisation had been conducted
less than a month before vaccination:
“Social mobilisation needed more time (than 2 weeks
before vaccination day) - it should start earlier and
continue until the last vaccination day.” (KII, Country 3)
Only 4/47 (1 %) experiences described duration and/or
frequency of mobilisation activities. Activities, including
community drama and/or radio broadcasts, were pro-
vided for 1 day or continuously over 1 to 2 weeks at vac-
cination venues. Social mobilisation activities sometimes
intensified as vaccination day approached:
“Mobilisation varied depending on the method used
to deliver the message or timing prior to actual
vaccination… mobilisation was conducted in the same
community once a week before vaccination started, to
daily on the vaccination week.” (KII, Country 33)
Rumour management
Rumours, reported in 13/37 (35 %) countries, were gen-
erally consistent in content and often spanned more
than one delivery experience per country. One country
reported rumours spreading from a neighbouring coun-
try. Rumours generally focused on whether HPV vaccine
affected fertility, caused dangerous side effects, or was
experimental (Table 2) [22, 27].
Experiences generally attempted to prevent rumours
and institutional refusals (e.g., refusal by schools or reli-
gious groups) by conducting intensive and repeated
sensitization activities (Table 2). Once rumours arose,
credible influencers were often mobilised to counteract
misinformation with targeted messages in specific com-
munities (Table 2). Government endorsement was also
reported as useful in mitigating rumours and increasing
vaccine acceptability if uptake was low [6, 22, 26, 28],
e.g., some experiences distributed government or WHO
letters of vaccine endorsement to allay parental concerns
(Table 2). However, in two experiences, rumours and
misinformation caused the withdrawal of government
endorsement and HPV vaccination was suspended [18].
Delays in addressing rumours, especially those around
severe side effects or that the demonstration project was
actually a clinical trial, resulted in vaccine delivery being
delayed in one country and stopping prematurely in two
countries, including India [18]. A prompt response was
critical for success, for example:
“[Rumours were] usually due to confusion around girls
being sterilised and other misconceptions. [They said]
‘Once again women are being used to pilot new
products’. [Rumours were] overcome through intensive
health messages and education.” (KII, Country 2)
Consent
In total, 50/72 (69 %) delivery experiences reported con-
sent procedures, 32 (64 %) of which also reported first-
dose HPV coverage. Of these, 18/32 (56 %) used opt-in
written parental consent, 11/32 (34 %) used opt-out im-
plied consent, and three (9 %) changed from written to
implied consent during implementation. Opt-in written
consent was defined as parents or guardians actively giv-
ing permission for daughters to be vaccinated by returning
a signed consent form. In addition to signing a consent
form, some experiences required parents/guardians to ac-
company daughters to vaccination venues. In three coun-
tries, girls were not vaccinated if the parent/caregiver
was not present [29]. Two national programmes had
added HPV vaccine to a pre-existing school health
programme consent sheet that included a range of
health interventions delivered to children over 5 years
old. Opt-out implied consent meant all girls were vac-
cinated except those whose parents or guardians formally
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refused vaccination or kept girls home on vaccination
days [10].
“[Written consent] is not used routinely, we developed
it for the new vaccine. The MOH advised us to use
consent as it was the first time the vaccine was used in
the country” (KII, Country 6)
Parents questioned why opt-in consent was required for
HPV vaccine but not others, such as measles or hepatitis
vaccines, and 13 experiences reported that using opt-in
consent resulted in rumours that the HPV vaccine was ex-
perimental. Ten of these 13 experiences had data on uptake
rates; four reported 64–70 % uptake and six reported 70–
90 % uptake. In addition to concerns about vaccine safety,
one informant described parental concerns that signing a
written consent form indicated they took full responsibility
for any consequences, including adverse events:
“For the girls to be vaccinated the project required
a lengthy consent form to be signed and returned to
the school. Parents/guardians felt that by signing
the form they would shoulder the blame in case of
daughter’s death or emergency following vaccination”
(KII, Country 14)
“Consent was opt-in for first year, which caused a lot
of challenges and suspicion” (KII, Country 2)
Delivery experiences using opt-out consent were more
likely to report higher coverage than those using opt-in
consent (Table 1). Lengthy consent procedures were re-
ported to reduce vaccination uptake, and eleven coun-
tries proposed simplifying consent forms or changing to
implied consent [25, 27]. One reported uptake increased
from 77 to 99 % on switching from opt-in to opt-out
consent, although other programme factors also changed
in the same time period. Another, on comparing uptake
using opt-in and opt-out strategies, switched to opt-out
as it drastically increased uptake. Four countries chan-
ged to opt-out consent because of rumours about the
vaccine being experimental and to better align with na-
tional consent policy for routine immunisation [25].
It should be noted that girls were not always passive in
the vaccination decision. Four countries reported that
girls who wanted to be vaccinated had persuaded their
parents/guardians to sign consent forms [11]. One ex-
perience allowed children aged 12 years and above to
legally consent to vaccination [30]. Four countries re-
ported that, despite parental consent, some girls refused
to be vaccinated.
Acceptability
In total, 45/72 (62 %) experiences reported on HPV vac-
cine acceptability in 23 of 37 countries. Of these, 14/45
(31 %) experiences in nine countries formally measured
acceptability in surveys, studies or post-introduction
Table 2 Reported rumours, institutional refusals, and management approaches
Reported rumours Management approaches (preventative and reactionary)
HPV vaccine is experimental/untested
(Countries 3, 12, 24)
• Rumours resulted from opt-in consent, which was changed to opt-out;
• Government and experts immediately addressed rumours.
HPV vaccination causes fertility problems
(Countries 8, 17, 21, 24, 31, 16, 28)
• Mobilisation was started very early and messages built into parent-teacher meetings;
• High-level advocacy using parliamentarians from the beginning of the programme;
• Intense mobilisation targeted anti-vaccination lobbyists;
• A reactive crisis response was organised, including meeting with communities.
Vaccine causes long-term adverse events, e.g., death, cancer
(Countries 28, 33, 35, 26)
• Adverse events were investigated and guardians reassured that it was not due to
vaccination.
There is another cure for cervical cancer other than vaccination
(Country 35)
• Rumours were tackled immediately with email newsletter and/or parent meetings.
Institutional refusals related to the vaccine Management approaches
Private/faith-based schools
(Countries 23, 24, 31, 35, 37)
• Sensitization through the community and targeted mobilisation using influencers;
• Media access to correct information so communities could obtain HPV vaccine
information from an independent source.
Churches/religious groups
(Countries 3, 28, 37)
• Increased face-to-face, community, and religious leaders’ meetings.
Community/parent groups
(Countries 1, 5, 6, 10, 14, 18, 23)
• Identified groups opposing vaccination were provided with more information;
• Frequent repetition of messages;
• Involved leaders and managed vaccination through government system;
• Provided additional training and information to health-workers and teachers.
Anti-vaccination lobbyists, human rights groups, academics
(Countries 12, 30)
• Provided additional media information and internet-based information campaigns.
Teacher and health-worker reluctance to vaccinate girls
(Countries 6, 23)
• Provided additional training to healthworkers and used peers to trace missing
and out-of-school girls.
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evaluations; the remainder reported acceptability without
detailed methods. Studies in three countries measured vac-
cine acceptability as parents’ and/or girls’ willingness to be
vaccinated and subsequent uptake of HPV vaccination
[31–33]. One study in one country specifically selected
vaccinated and unvaccinated girls to survey [22]. Accept-
ability in the remaining five countries was measured in
community coverage surveys [6, 26, 27, 30, 34–37]. One
study also measured acceptability among health workers as
nurse’s willingness to recommend HPV vaccination [38].
Publications on experiences in Brazil, Cameroon, Kenya,
Peru, South Africa, Tanzania, Uganda, and Vietnam re-
ported parental acceptability [6, 22, 27, 30–32, 37–39]. Ac-
ceptability among girls was reported in Cameroon,
Tanzania, Uganda, and Vietnam [22, 26, 33, 35, 36]:
“Interestingly, girls who did not normally attend
schools would often come to the school on vaccination
day to receive their vaccines.” (KII, Country 25)
Studies of hypothetical acceptance prior to vaccination
were excluded from this study; the reason was illustrated
by a Kenyan study that reported low first-dose uptake
despite recording high parental willingness to vaccinate
at baseline [32]. The most common reasons reported in
post-vaccination surveys for parental acceptance or re-
fusal of HPV vaccine are shown in Table 3. Communi-
cating directly with influencers such as family members,
teachers and health-workers was reported as strongly as-
sociated with acceptability [22, 26, 27, 31], as was being
well-informed about HPV, HPV vaccination, and cervical
cancer [27, 30, 32, 35, 40]. Exposure to rumours and in-
correct or limited information about HPV vaccine safety,
side effects and association with cervical cancer, were as-
sociated with low acceptability [27, 33, 35, 37–39].
Vaccination refusal by private schools, religious groups
and health professionals was reported in 15 countries
(Table 2). In five experiences, some school principals or
teachers would not allow vaccinators into their schools
due to fear of parent reactions, religious beliefs, or ru-
mours [22, 41]. In two experiences, the school adminis-
tration thought that they would be held responsible for
any severe adverse effects. In Tanzania, parental refusal
was higher in private than public schools, as school
management feared loss of revenue if parents objected
to vaccination [42]. In one experience, school adminis-
trators in 23 schools refused access to health-workers as
some parents did not consent to vaccination. The im-
portance of training key influencers in the community
was emphasized by many KIIs:
“At first religious leaders were not specifically targeted
for mobilisation but we soon realised they had a
powerful influence in the communities so they were
included in the social mobilisation during the first
year. Low level of social mobilisation of out of school
girls yielded low uptake at community outreach events
and at the health facility. Rumours may have also had
an influence but after this was realised social
mobilisation was increased.” (KII, Country 22)
Table 3 Reasons for accepting or rejecting HPV vaccination
reported in surveys in 8 countriesa
Reasons for acceptance stated by parents/guardians Scoreb Surveys
(n)
Protection from cancer 23 8
Vaccination is good for health 22 8
Perceived cervical cancer risk or susceptibility 8 3
Convincing information 6 3
Vaccine is safe 5 2
Following others’ advice 5 3
Protection from infection 5 4
Informed about the programme 4 2
Vaccine is free 3 2
To avoid shame/stigma of an STI infection 2 2
Interest in HPV vaccine and education 2 1
Heard of cancer/knowledge of someone with cancer 1 1
Perceived severity of infection and consequences 1 1
Provided at school to every child 1 1
Reasons for not starting stated by parents/guardians
Lack of motivation
Fear of adverse effects on fertility and vaccine safety 16 8
Girls or parents do not want vaccine 6 3
May encourage early sex 4 2
Cancer considered low severity/low risk 3 1
Concern about vaccine effectiveness 3 1
Undisclosed reasons 2 1
Perceived low risk of infection 2 1
Not good for a child 1 1
Lack of information
Not aware of the programme 13 6
Insufficient information 8 4
Systems barriers
Absenteeism 15 7
Difficult to determine age eligibility 9 7
Location and time not convenient 2 1
Health provider didn’t recommend 1 1
aFregnani JHTR, 2013; Kury CMH, 2013; Wamai RG, 2012; Wamai RG, 2012;
Vermandere H, 2014; Botha MH, 2014; Watson Jones D, 2012; Katagwa, 2014;
Galagan, 2013
bThe most common reason cited within each survey was given a score of 3,
the second most common scored 2 and the third most common reason
scored 1. Reasons were then pooled with their scores to indicate the most
commonly cited reasons across all surveys
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“The anxiety among the health workers in the
first campaign was high as they thought it was
potentially dangerous. [We] need to spend a lot
more time with health professionals to educate
them fully” (KII, Country 30)
Systems barriers, not necessarily related to acceptability,
also affected uptake. For example, school absenteeism on
vaccination days was reported as a major barrier to HPV
vaccine uptake [6, 28, 32, 35, 37, 42, 43]. Additionally, in-
adequate official communication about vaccination timing
and/or venue and difficulties determining age eligibility
were reported by experiences in India, Kenya, Nepal, Peru,
Uganda, and Tanzania [6, 28, 32, 42–44].
Discussion
Key findings
Social mobilisation data were available from 65 % of de-
livery experiences covering 30 LMICs. Sources reported
social mobilisation was essential for high HPV vaccine
acceptability and coverage, though few experiences
formally evaluated different mobilisation strategies [6].
Approaching a range of target audiences, including girls,
parents, and influencers, appeared to help broaden
support for HPV vaccination. Focusing messages on cer-
vical cancer protection, rather than STI prevention, ap-
peared to help minimise sensitivities around girls’
sexuality [9, 10, 16, 17]. Grey literature identified inter-
active communication as the most effective when par-
ents were asked about their sources of information
about the vaccine and influencers on their decision.
While few experiences reported on timing and duration
of mobilisation activities, early initiation and increasing
intensity appeared most effective. Social mobilisation for
HPV vaccination, especially during introductory phases
and alongside provider training on risk communication,
was reported as more rigorous and frequent than mobil-
isation for routine infant vaccination to mitigate risks
associated with rumours [3, 7, 21, 45]. Rumour manage-
ment was a key aspect of social mobilisation, requiring
both preventive sensitisation and rapid reactive risk miti-
gation [18, 19].
Consent data were available from 69 % of experiences.
Written opt-in consent was common for HPV vaccin-
ation, due to WHO recommendations on consent [7].
However, opt-in approaches sometimes contributed to
parental worries about vaccine safety, particularly in
countries using opt-out, implied consent for routine vac-
cination. Forms could be lost or submitted late, even
among households that did not object to HPV vaccin-
ation. Implied opt-out consent was associated with
higher first-dose coverage, as it was more often in-line
with other routine immunisation procedures and na-
tional policy, though causation cannot be assumed.
Acceptability data were available from 62 % of experi-
ences. HPV vaccination was generally well accepted
among individuals and communities in LMICs. Similar
acceptability rates have been reported for other newly
introduced vaccines targeting adolescents and school-
age children in high-income countries, such as Tdap,
meningococcal conjugate (MCV4), and influenza vac-
cines [46, 47]. The role of national and community influ-
encers supports findings for other vaccines targeting
adolescents, including Tdap and MCV4 [48].
Implications
The positive association between intensive, interactive
social mobilisation and first-dose coverage supports
existing communication recommendations around vac-
cine introduction strategies [7, 21]. Formative research
prior to the development of communications strategies
provided generally consistent results across HPV deliv-
ery experiences, indicating further formative research on
effective communication strategies in other LMICs
might not be needed [49–51]. Findings indicated that so-
cial mobilisation and training of ‘credible influencers’
should start sufficiently early to allow parents/guardians
time to consult well-informed sources [7, 17, 27]. While
mobilisation timing was not associated with first-dose
uptake, many factors influence uptake and the import-
ance of timely social mobilisation was a common theme
in interviews. WHO recommends initiating social mobil-
isation 3 months prior to starting HPV vaccination [7].
Findings indicated that particular mobilisation efforts
should focus on out-of-school girls and non-government
(private) or faith-based schools, where refusals were
highest, particularly in countries where primary delivery
strategies are school-based.
Informed consent is enshrined in medical ethics and
international human rights law [52]. While those below
the age of consent should be protected and informed
consent ethics respected [10, 53, 54], the requirement
for opt-in written parental consent for HPV vaccination
has been reported as problematic. The requirement for
parental consent can affect utilisation of adolescent
health services and the potential negative impacts on
vaccination uptake must be considered [9, 10, 55].
Where opt-in written parental consent is used, particu-
larly if this differs from routine vaccination, reasons
should be explained clearly and procedures kept
straightforward [10, 56]. Some countries have already re-
duced the age of consent to enable girls to choose HPV
vaccination [10, 30]. Opt-out, implied, consent was ac-
ceptable in countries in which it was documented and
associated with fewer difficulties, and thus several coun-
tries have changed from opt-in to opt-out consent. In-
formed consent procedures for routine healthcare
interventions in many LMICs need to be improved [10],
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developing a school health programme consent sheet
that is signed at school enrolment may be the most effi-
cient option for school-based HPV vaccination.
Acceptability was most readily affected by rumours
and misinformation. Rumours were remarkably similar
in content across geographical regions. This suggests
messages could be tailored from the outset to address
concerns about experimental vaccines and effects on fer-
tility, to pre-empt anticipated concerns [44, 57, 58]. Ex-
periences from Uganda and Peru indicated that simple
messages, emphasizing health benefits to girls, were as
effective in gaining high vaccination uptake as more
complicated messages [59]. Similarly, simplified mes-
sages were found to increase uptake of measles, mumps,
and rubella vaccination for infants [60], supporting the
communications benefits of simple, clear messaging.
Limitations
This study had several limitations. First, approximately
30 % of experiences did not report on social mobilisation,
so it was unclear whether social mobilisation had been
done or how effectively. Second, depth and quality of so-
cial mobilisation data, especially in unpublished reports,
varied considerably. Interviews helped to fill gaps in these
reports, but were usually conducted with EPI managers or
project/programme representatives who were not always
familiar with all aspects of social mobilisation implemen-
tation, consent, and acceptability. Third, associations
found between mobilisation and first-dose coverage can-
not be interpreted as causal, as sources used different
study designs and outcome measures. Countries with
poorer social mobilisation (e.g., non-interactive ap-
proaches) may have had weaker health systems, less
money to deliver sophisticated mobilisation, and/or inef-
fective vaccine delivery strategies. Implementation and
reporting of delivery experiences was heterogeneous, with
many factors influencing first-dose coverage.
Conclusions
HPV vaccine delivery experiences in LMICs to-date
underscore the value of effective social mobilisation. To
allow sufficient time to address concerns and misconcep-
tions, mobilisation should be initiated as soon as possible
and conducted systematically. Mobilising credible influen-
cers, who are trusted by the community, as well as na-
tional figureheads and/or celebrities, can increase public
confidence and therefore vaccination coverage. Simple
messages that build interactively on existing knowledge of
cancer risks appear more effective than either complex or
non-interactive approaches. Consent procedures should
be considered carefully, to balance informed consent with
public health benefits. High acceptability and uptake of
HPV vaccination was achievable despite minimal vaccin-
ation and health knowledge in many communities.
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